Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 2, Open Label Study Evaluating Subcutaneous Administration of Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

NCT05704049 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05704049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05704049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 2, Open Label Study Evaluating Subcutaneous Administration of Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 5, 2023
Completion date
May 12, 2028
Enrollment
118 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma